(Q37541561)

20 August 2017

1 reference

title

Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases (English)

1 reference

systemic lupus erythematosus

20 August 2017

1 reference

1 reference

1 reference

Manuel Ramos-Casals

1

0 references

Munther A. Khamashta

series ordinal

4

object named as

M A Khamashta

1 reference

20 August 2017

M J Soto

2

1 reference

PubMed ID

19578100

20 August 2017

M J Cuadrado

series ordinal

3

1 reference

20 August 2017

1 August 2009

1 reference

20 August 2017

1 reference

20 August 2017

18

1 reference

20 August 2017

9

1 reference

20 August 2017

767-776

1 reference

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.

20 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXII. Predictors of time to the occurrence of initial damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

How to improve morbidity and mortality in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

The B cell in systemic lupus erythaematosus: a rational target for more effective therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

Common variable immunodeficiency in a patient with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

Infective endocarditis complicating rituximab (anti-CD20 monoclonal antibody) treatment in an SLE patient with a past history of Libman-Sacks endocarditis: a case for antibiotic prophylaxis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

SLE-associated transverse myelitis successfully treated with Rituximab (anti-CD20 monoclonal antibody).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

Anti-CD20 therapy for inducing and maintaining remission in refractory systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

Remission of refractory lupus nephritis with a protocol including rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

Six refractory lupus patients treated with rituximab: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

Rituximab treatment for immune thrombocytopenia associated with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

Rituximab (anti-CD20 monoclonal antibody) for refractory systemic lupus erythematosus: report of one case

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

Hypocomplementemic urticarial vasculitis with angioedema, a rare presentation of systemic lupus erythematosus: rapid response to rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

Successful rituximab-CHOP treatment of systemic lupus erythematosus associated with diffuse large B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

Management of therapy-resistant systemic lupus erythematosus with rituximab: report of a case and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

Consensus statement on the use of rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

Autoimmune diseases induced by TNF-targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

The Janus of lupus--benefits and risks with B-cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309106174

21 January 2018

Identifiers

DOI

10.1177/0961203309106174

1 reference

20 August 2017

1 reference

PubMed ID

19578100